Cited 0 times in
진행성 간암에서 전신 요법
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최혜진 | - |
dc.date.accessioned | 2014-12-20T17:41:33Z | - |
dc.date.available | 2014-12-20T17:41:33Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 1598-6314 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/95081 | - |
dc.description.abstract | Understanding the mechanism of hepatocarcinogenesis has provided the opportunity to evaluate the efficacy of molecularly targeted agents in HCC. Sorafenib is a multikinase inhibitor with antiangiogenic, proapoptotic, and Raf kinase inhibitory effects, and it is the first new agent to consistently prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). The success of sorafenib is a milestone for systemic therapy of HCC, shifting the paradigm of systemic treatment to molecular targeted agents. Many novel agents that inhibit angiogenesis, epidermal growth factor receptor, and mammalian target of rapamycin are under clinical development. This review attempts to summarize the current status and future perspectives of systemic therapy in HCC. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 33~39 | - |
dc.relation.isPartOf | Journal of the Korean Liver Cancer Study Group (대한간암연구회지) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | 진행성 간암에서 전신 요법 | - |
dc.title.alternative | Systemic Therapy in Advanced Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | 최혜진 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04219 | - |
dc.relation.journalcode | J01832 | - |
dc.identifier.url | http://kiss.kstudy.com/journal/thesis_name.asp?tname=kiss2002&key=3009645 | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | Sorafenib | - |
dc.subject.keyword | Molecular targeted agent | - |
dc.contributor.alternativeName | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | Choi, Hye Jin | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 11 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 33 | - |
dc.citation.endPage | 39 | - |
dc.identifier.bibliographicCitation | Journal of the Korean Liver Cancer Study Group (대한간암연구회지), Vol.11(1) : 33-39, 2011 | - |
dc.identifier.rimsid | 28078 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.